miRNAs are small non-coding RNA molecules that are about 20-25 nucleotides in length and are transcriptional regulators [1]. miRNA can control the expression of genes involved in processes such as development, differentiation, proliferation and apoptosis and play an important role in cancer. Moreover, miRNA can regulate the expression of more than 30% of protein-coding genes and interestingly, more than 50% of miRNA genes are located in cancer-associated genomic regions, suggesting they possess a role in the pathogenesis of human cancers [2, 3].

The first miRNA (lin-4) was discovered in 1993 [4] and since then, hundreds if not thousands of miRNAs have been identified and added to various databases including (microRNA.org and MirBASE.org). Understanding the function of miRNA stems from appreciating their production, which begins with the transcription of primary transcripts called pri-miRNAs by RNA polymerase II [5]. Pri-miRNAs range from hundreds to thousands of nucleotides in length and so must undergo three cleavage steps before their activation to regulate genes [6]. Processing begins in the nucleus using ribonuclease the Drosha and DGCR8 (DiGeorge syndrome critical region 8) complex to form an intermediate hairpin called a pre-miRNA of about 70-100 nucleotides long [7]. The pre-miRNA is transported out of the nucleus by exportin-5 and taken to the cytoplasm to be converted to an 18-25 nucleotide [8], then mature double-stranded miRNA is processed using a ribonuclease named Dicer. Subsequently, the miRNA double-strand is separated to form a mature, active miRNA using an effector complex called RNA-induced silencing complex (RISC)[9]. Following the formation of this mature miRNA, the specific complementary
region of the 3’ untranslated region (UTR) of a messenger RNA (mRNA) can be targeted [10]. Upon binding of the mRNA and miRNA, the RISC complex induces degradation of the double-stranded mRNA [10]. Another possible mechanism that miRNAs use is the blocking of protein translation processes, therefore resulting in the elimination of that specific protein that is being expressed [11].

Examination of tumour-specific miRNA expression profiles has revealed that miRNAs could be master regulators of many aspects of tumour biology [1]. Many studies have shown that miRNA themselves can function as tumour suppressor genes or oncogenes, where gene repression or overexpression can have a diagnostic and prognostic significance [1, 12]. The tumour suppressor miR-98, for example, was identified by Johnson et al [13] to be reduced in some tumours resulting in amplified Ras oncogene activation and thereby aberrantly increasing the proliferation of cells [13]. In contrast, upregulation of oncogenic miR-17 by cMyc was found to affect cell cycle control mechanisms and to disrupt the apoptotic regulator E2F1 [14]. Following these key discoveries in 2005, many correlations between miRNA expression, with Weinberg’s six hallmarks of cancer having been established [15].

Despite the surge in epigenetic research in the last decade, the roles of miRNA in many human cancers such as leukaemia and lymphoma have not been clearly defined. Manipulation of miRNA regulation could be a novel approach to achieving an understanding for the regulatory mechanisms of miRNA in cancer. Changes in the expression of a number of transcription factors have been associated with various blood cancers [16, 17], with increasing evidence supporting a role for the regulation of transcription factors by miRNAs [10].

This review reports data published about the miRNAs which directly target the NF-κB pathway in human cancer with particular emphasis on leukaemia, myeloma and lymphoma. It also describes the molecular mechanisms underlying miRNA and NF-κB dysregulation in these haematological malignancies.

NF-κB and human cancer

NF-κB proteins are dimeric transcription factors that induce the expression of genes involved in cell survival, proliferation and in immune responses [18]. NF-κB is activated by many stimuli, including pro-inflammatory cytokines such as tumour necrosis factor-α (TNF), interleukin-1β (IL-1β) and epidermal growth factor (EGF) [19, 20]. There are two main pathways involved in NF-κB signalling, namely the classical pathway (which is mostly involved in the activation of innate immunity) and the alternative pathway (required for the development of lymphoid tissue)[18-21]. NF-κB is composed of five subunits named p65 (RelA), RelB, cRel, p50 and p52 (Figure 1). In unstimulated cells, NF-κB is located in the cytoplasm whereby its nuclear localisation sequences are masked, enabling NF-κB to be retained in an inactive state [18]. The classical NF-κB pathway is initiated by various stimuli including TNF which through its receptors can activate TNF receptor-associated factor (TRAF) adaptors. Following this, activation of the IκB kinase (IKK) kinase complex causes phosphorylation of IκB proteins and triggers their proteosomal degradation [22]. In turn, the NF-κB subunits translocate from the cytoplasm to the nucleus and bind to the κB complex as dimers, including p50/p65 and p65/cRel. This enables transcription of a plethora of genes that drive inflammation as well as regulating apoptosis (eg TNF, survivin and FLIP) [23, 24]. The classical NF-κB pathway is constitutively active in many blood cancers, including myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML), acute lymphocytic leukaemia (ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), lymphomas and in multiple myeloma (MM)[16, 25, 26]. Constitutively active NF-κB results in the deregulated expression of NF-κB controlled genes and can have advantageous survival effects for the cancer cell. For example, overexpression of anti-apoptotic genes such as surviving, FLIP and IAPs can enhance the cells ability to resist cytotoxic chemotherapy [17, 20, 27].

The overexpression of NF-κB and its anti-apoptotic cytoprotective effect suggests that it might be a useful therapeutic target for the treatment of haematologic malignancies. Several drugs effective for the treatment of MM, including proteasome inhibitors, thalidomide, lenalidomide and arsenic trioxide, block NF-κB activation [28-32]. New agents with NF-κB inhibitory activity enhance the anti-MM effects of conventional chemotherapeutic agents and re-
MicroRNA control of NF-κB in blood cancers

Triptolide (diterpenoid triepoxyde), a purified component of a traditional Chinese medicine, extracted from a shrub-like vine named Tryptoerygium wilfordii Hook F (TWHF) inhibits transcriptional activation of NF-κB and downregulates the expression of various NF-κB-regulated genes [33]. Triptolide induces apoptosis of MM cells and effectively inhibits cell growth of MM cells. NF-κB activation can be also inhibited by IKKβ-selective inhibitors, PS-1145 dihydrochloride, MLN120B (Millennium Pharmaceuticals)[30, 34] and BMS-345541 (Bristol-Myers Squibb)[35]. LC-1 the dimethylamino-parthenolide derivative demonstrated significant cytotoxicity to AML blasts targeting NF-κB [36]. Taken together these data suggest a multidrug approach to target NF-κB in human cancers, however with the knowledge that we need a more complete understanding of how miRNA targets NF-κB, we are still a long way from effectively manipulating NF-κB pathways in human disease.

miRNA and human blood cancers

In 2004 Chen and colleagues first established the connection between miRNAs and haematopoiesis regulation, determining that individual haematopoietic cell types differentially expressed miRNAs, given that the same miRNAs were not always expressed in all lineages [37]. Their findings suggested that the specific miRNAs are induced during lineage differentiation and could influence haematopoietic lineage differentiation in mice, although differences in the expression pattern of the same miRNAs in humans have been reported [38-40]. Moreover, mature miRNAs were found to regulate haematopoietic differentiation-associated mRNA on CD34+ cells, and especially miR-155 represented an inhibitor of haematopoietic stem progenitor differentiation [41]. It has also been reported that members of the miR-30 family by targeting the transcription factor PRDM1, regulate the differentiation of lymphocytes to...
MicroRNA control of NF-κB in blood cancers

plasma cells [42, 43]. More than the deregulation of miRNAs, haematopoietic deletion of AGO2 or of Dicer resulted in disruption of erythroid precursors, with severe anemia, splenomegaly, and maturation arrest of erythroid precursors. Aberrant miRNA expression profiles have been reported in almost all types of haematological malignancies, including various types of NHL, Hodgkin lymphoma, CLL, AML, APL, ALL and MM [44-48].

The potential use of miRNAs as prognostic markers in clinical practice has already been demonstrated, as expression levels of miRNAs could predict the time to first treatment in CLL patients, were associated with mutations of established molecular prognostic factors [49], and were also associated with overall survival in patients with hepatocellular carcinoma, pancreatic cancer, colon adenocarcinoma, lung cancer, esophageal cancer, and melanoma. Moreover, miRNAs have been evaluated in the context of chemosensitivity to assess the individual chemoresponse in both in vitro and in vivo models [43, 50]. The measurement of miRNAs levels in plasma or serum has rendered them useful in the diagnosis of solid malignancies such colorectal cancer, lung, prostate, and kidney cancer. However, it has not been elucidated whether miRNA circulating levels are tumour-created or represent a systemic response, and it is not clear yet which is the best specimen among serum, plasma, or peripheral blood mononuclear cells, used for the miRNA signature detection. The important functions of miRNAs in cancer make them attractive therapeutic targets, therefore efforts should be made to identify which miRNAs could be used to achieve clinical benefits against cancer [51].

There is convincing evidence for a major role of miRNAs in cancer. This connection was first suggested in 2002 by Calin et al [52], with the discovery that miR-15 and miR-16 were located on chromosome 13q14, a region frequently deleted in CLL. Upon examining the expression levels of these miRNAs, miR-15 and miR-16 were reduced or eliminated in 68% of all CLL cases tested [52]. They also noted that the 13q14 deletion was frequently the only genetic abnormality in patients and thus the deletion of miR-15/16 may be a direct cause of CLL. Upon examination of genomic locations of miRNAs, they reported that many miRNA-coding regions are located in fragile regions of the genome that are frequently amplified or deleted in many cancers, arguing that gain or loss of miRNAs were selected for in cancerous cells and underlie important tumourigenic steps [53].

Global expression profiling revealed alterations of miRNA expression patterns first in CLL [2] and then in other malignancies [54]. These studies reviewed by Munker et al [54] showed that the expression of several miRNAs (miR-17-5p, miR-20a, miR-21, miR-92, miR-106a and miR-155) was increased in the majority of tumour types, arguing that these may be common oncogenic miRNAs. It was also noted in these studies that miRNA expression patterns could distinguish tumours and tissue types, indicating that miRNA expression levels may be useful biomarkers for cancer. Such miRNA expression patterns were then found to be associated with poor prognosis of CLL and lung cancer, offering further demonstration of such potential. Subsequent mechanistic studies demonstrated that alteration of specific miRNAs could affect cell proliferation, apoptosis, tumour growth and angiogenesis in mouse models. Altogether, the evidence is convincing that alterations of miRNAs occur during and contribute towards leukaemogenesis.

miRNA that modulate NF-κB signalling

The role of miRNA in regulating the NF-κB pathway is not fully appreciated especially in blood cancers, particularly since a large proportion of blood cancers have constitutively active NF-κB. This section will hopefully allow the reader to digest the influence of miRNA on the NF-κB pathway. Figure 1 shows the miRNAs that directly target specific elements in one of the three NF-κB pathways (from published data only). Table 1 lists and references the miRNA involved in regulating NF-κB pathways in human blood cancers. Moreover, we also describe the influence of NF-κB on miRNA expression.

To begin this section we will start with probably the most well known miRNA, miR-146a. Mir-146a is a member of the miR-146 miRNA family, consisting of two evolutionary conserved miRNA genes: miR-146a and miR-146b. In people, these loci are located on separate chromosomes, in quite unrelated sequence contexts, but differ in their mature sequence only by 2 nucleotides at the 3’ end. Initially, it was shown that both genes respond to lipopolysaccharide
MicroRNA control of NF-κB in blood cancers

Table 1. Key miRNA in regulating NF-κB pathways in human blood cancer.

<table>
<thead>
<tr>
<th>miR</th>
<th>MiRNA/Disease/Cell</th>
<th>Function/Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-9</td>
<td>NF-κB1</td>
<td>Down-regulated in human ovarian cancer correlating with high levels of NF-κB1 [62].</td>
</tr>
<tr>
<td>miR-10a</td>
<td>MAP3K7/βTRC/AML/CML</td>
<td>Over-expressed in AML and down-regulated in CML [59] [60].</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Targets both MAP3K7 and βTRC, key regulators of IkBα [61].</td>
</tr>
<tr>
<td>miR-15a/-16</td>
<td>Bcl2/IKKα/CLL</td>
<td>Decreased during monocyte-macrophage differentiation, correlating with an increase in IKKα, p52 and a stabilisation of NIK [45]. Deleted in 68% of CLL cases [52].</td>
</tr>
<tr>
<td>miR-146a</td>
<td>TRAF6/Mycel sarcoma/Adult T-cell leukemia</td>
<td>Expression is NF-κB dependent and feeds back to inhibit NF-κB by targeting an adaptor protein TRAF6 [55]. Loss drives development of myeloid malignancies [56]. Over-expression enhances growth of T-cells [58].</td>
</tr>
<tr>
<td>miR-155</td>
<td>TP53INP1/CLL/AML/CML</td>
<td>Can induce hyperproliferation of B cells [39]. Over-expression correlates with repression of pro-apoptotic tumour p53-induced nuclear protein 1[40].</td>
</tr>
<tr>
<td>miR-223</td>
<td>NFI-A/IKKα/Ovarian cancer</td>
<td>Co-regulated with miR-9 in ovarian cancer [72]. Decreased during monocyte-macrophage differentiation, correlating with an increase in IKKα [45].</td>
</tr>
</tbody>
</table>

in human monocytes, but only miR-146a is processed to a mature form, with induction of expression of miR-146a an NF-κB dependent process [55]. Based on further work miR-146a was shown to act as a negative feedback regulator of the NF-κB by targeting two adapter protein, TRAF6 (TNF receptor–associated factor 6), which is crucial for NF-κB signalling [55]. Also, Zhao et al have recently shown that knock-out of miR-146a gene in mice leads to histologically and immunophenotypically defined myeloid sarcomas and some lymphomas [56]. In adult T-cell leukaemia (which is an aggressive and fatal CD4+ T-cell malignancy) the human T-cell leukaemia virus type 1 (HTLV-1) which is the causative agent of this disease, up regulates miR-146a [57]. In another study, HTLV-1 induced Tax protein to up-regulate miR-146a expression in a NF-κB-dependent manner which results in the inhibition of miR-146a target genes [58]. Inhibition of miR-146a function by an anti-miRNA inhibitor reduced the proliferation of HTLV-1-infected T-cell lines but not that of uninfected T-cell lines. Moreover, overexpression of miR-146a enhanced the growth of an HTLV-1-infected T-cell line. These findings suggest that miR-146a is a potentially suitable therapeutic target of adult T-cell leukaemia.

miR-155 is another oncogenic miRNA [124] that is regulated in a NF-κB dependent manner and associated with a number of different blood cancers including CLL [39], AML and CML [40, 44]. Increased miR-155 expression can also be found in the bone marrow of leukaemic patients and over-expression of miR-155 in mouse models causes hyperproliferation of B-cells, a common hallmark of leukaemia and lymphoma [102]. Over-expression of miR-155 also causes the repression of tumour p53-induced nuclear protein 1, which is a pro-apoptotic gene downstream of p53 signalling [129]. The suppression of tumour p53-induced nuclear protein 1 is a likely mechanism for pro-tumourigenic functions of miR-155 and a possible mediator of inflammation-induced carcinogenesis.

Another very interesting miRNA is miR-10a, which has been found to be overexpressed in association with NPM1 mutations and MDM4 downregulation in intermediate-risk AML [44, 59]. Moreover, mir-10a is also down-regulated in 71% of newly diagnosed CML patients [60]. In a separate study by Fang et al [61], it was shown that phosphorylation of IkBα (a prerequisite for IkBα proteolysis and NF-κB activation) was significantly up-regulated in miR-10a knock-down cells and was accompanied by increased nuclear expression of NF-κB p65. Conversely, knock-in of miR-10a (a conservative 25-fold increase) inhibited the basal expression of VCAM-1 and E-selectin. Two key regulators of
IκBα degradation mitogen-activated kinase kinase kinase 7 (MAP3K7; TAK1) and beta-transducin repeat-containing gene (betaTRC) contain a highly conserved miR-10a binding site in the 3’ UTR. Both molecules were up-regulated by miR-10a knock-down and suppressed by miR-10a knock-in, and evidence of direct miR-10a binding to the 3’ UTR was demonstrated by luciferase assay. Taken together these experiments demonstrate a direct link between mir-10a and NF-κB regulation which could be influential in leukaemogenesis [61].

miR-9 has emerged as a regulator of NF-κB in another study that has shown that miR-9 is downregulated in human ovarian cancer relative to normal ovary, and overexpression of miR-9 suppresses cell growth in vitro. Furthermore, the 3’-UTR of p50 NF-κB1 mRNA is found to be regulated directly by miR-9, demonstrating that NF-κB1 is a functionally important target of miR-9 in ovarian cancer cells. When miR-9 is over-expressed in ovarian cancer cells, the mRNA and protein levels of NF-κB1 are both suppressed, whereas inhibition of miR-9 results in an increase in NF-κB1 expression levels. Ovarian cancer tissues display significantly lower expression of miR-9 and a higher level of NF-κB1 compared with normal tissues, indicating that regulation of NF-κB1 by miR-9 is an important mechanism for miR-9 to inhibit ovarian cancer cell proliferative processes.

Deregulation of miR-15a and miR-16 in human CLL have been shown in the majority of patients as highlighted previously [39]. In another study by Hanlon et al [45] miR-15a and miR-16 were decreased considerably during human monocyte-macrophage differentiation, and expression of the miRNAs miR-223, miR-15a and miR-16, which led to higher expression of the serinethreonine kinase IKKα in macrophages [45]. In macrophages, higher IKKα expression in conjunction with stabilization of the NF-κB-inducing kinase, NIK, induced larger amounts of p52 NF-κB2. Moreover, with the knowledge that p52 and bcl-3 genes being involved in chromosomal translocations described in chronic and myeloid leukaemias [62], this is a major finding that links both NF-κB regulation and miRNA in the tumourigenic nature of these types of leukaemia.

The final part of this section examines the capacity for virus-induced miRNA manipulation of the NF-κB pathway. In this section we have previously touched on the role of HTLV-1 in upregulating miR-146a and its role in causing adult T-cell leukaemia. Another example of viruses regulating NF-κB is published by Lei et al [63] which showed that in Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8), deletion of a miRNA cluster from the KSHV genome causes reduced NF-κB activity [63]. Down-regulation of NF-κB activity was due to binding of the viral miRNA (miR-K1) to the 3’UTR of the IκBα inhibitor, therefore silencing its expression. Moreover with the knowledge that HSHV is known to be associated with different types of lymphoproliferative disorders [64], it is highly likely that miR-K1 could be the cause of high nuclear NF-κB levels in the majority of infected KSHV-associated blood cancers. The role of Epstein-Barr virus (EBV) in regulating miRNA which targets or regulates NF-κB should also be mentioned here. It has been shown over the past few years that EBV-encoded latent membrane protein 1 (LMP1) is a functional homologue of the TNF receptor family and contributes substantially to the oncogenic potential of EBV by inducing a number of miRNAs through its capacity to activate the NF-κB pathway including miR-155 and miR-146a [65, 66]. Taken together with the plethora of publications regarding the involvement of EBV in pathogenesis of human blood cancers, it is inevitable that this virus can induce miRNAs which regulate the role of NF-κB, ultimately leading to the oncogenic and chemoresistant nature of many of those associated cancers.

**miRNA-targeted therapy**

The discovery of small noncoding RNA molecules that repress translation has provided the research community with an opportunity to control the expression of specific genes. Small-molecule inhibitors and monoclonal antibodies have led to many successful therapies in cancer [67], however many cancer targets are difficult to inhibit and some inhibitors have many off-target side-effects and as such, possess undesirable toxicity [68]. It is possible that future cancer therapeutics could use small complementary miRNA sequences known as anti-miRs or antagomiRs to inhibit oncogenic miRNA activity, while miRNA mimics themselves could enable tumour suppressor gene function to be restored in a tumour cell [69]. The potential use of miRNA mimics and anti-miRs have also
been associated with many treatment advances in diverse fields of disease including cardiac disease and allergic airway diseases [70, 71]. The most promising approach proposed is to employ miRNA mimics, which can restore miRNA function that is lost within a disease. This approach uses synthetic oligonucleotides which are identical in sequence to endogenous miRNAs, and replicate their response. The second approach is to employ anti-miRs which repress rather than mimic responses of endogenous miRNAs; towards which means several approaches have been employed including: antisense oligonucleotides; miR-sponges and sponge constructs; synthetic oligonucleotide miR-masks; as well as potential small molecule inhibitors [70, 71]. The limiting factor in the use of either anti-miRs or miRNA mimics is the delivery of these agents into cells. The limiting factor in their use presently is the delivery of these agents into cells. However, their future pharmacological use is enormous and their potential to treat a variety of human cancers (not just blood cancers) should be planned.

Concluding remarks

During the past decade, much has been uncovered regarding the role of NF-κB in supporting tumourigenesis in various cancers. It is now also known that miRNAs target many genes that affect the activity of the NF-κB pathways, however, after reviewing the role of miRNA in regulating specific NF-κB subunits or kinases, we have shown that less is known about this process (Figure 1). This suggests that there is still a huge amount to discover regarding the impact of miRNA on NF-κB signalling and the system’s usefulness in battling cancer.

Acknowledgements

The authors thank the Association for International Cancer Research, Leukaemia and Lymphoma Research, The Big C and the University of East Anglia for support.

Conflict of interest

The authors declare they have no conflicts of interest.

Address correspondence to: Dr. David J. MacEwan, School of Pharmacy, University of East Anglia, Norwich, NR4 7TJ, United Kingdom. Tel: +44 (0)1603 592005; Fax: +44 (0)1603 452003; E-mail: d.macewan@uea.ac.uk

References

MicroRNA control of NF-κB in blood cancers


MicroRNA control of NF-κB in blood cancers


[51] Tomita M, Tanaka Y, Mori N. MicroRNA miR-146a is induced by HTLV-1 tax and increases the growth of HTLV-I infected T-cells. Int J Cancer 2011;in press.


[53] Fang Y, Shi C, Manduchi E, Civilek M, Davies PF. MicroRNA-10a regulation of proinflamma-
MicroRNA control of NF-κB in blood cancers